Treprostinil administration by inhalation
Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
1. A method of treating pulmonary hypertension comprising:
administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising from 200 to 1000 μg/ml of treprostinil or a pharmaceutically acceptable salt thereof
with a pulsed ultrasonic nebulizer that aerosolizes a fixed amount of treprostinil or a pharmaceutically acceptable salt thereof per pulse,
said pulsed ultrasonic nebulizer comprising an opto-acoustical trigger which allows said human to synchronize each breath to each pulse,
said therapeutically effective single event dose comprising from 15 μg to 90 μg of treprostinil or a pharmaceutically acceptable salt thereof delivered in 1 to 18 breaths.
2. The method of claim 1 , wherein the formulation comprises 600 μg/ml of the treprostinil or its pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the single event dose is not repeated for a period of at least 3 hours.
4. The method of claim 1 , wherein the single event dose produces a peak plasma concentration of treprostinil about 10-15 minutes after the single event dose.
5. The method of claim 1 , wherein the fixed amount of treprostinil or its pharmaceutically salt for each breath inhaled by the human comprises at least 5 μg of treprostinil or its pharmaceutically acceptable salt.
6. The method of claim 2 , wherein the fixed amount of treprostinil or its pharmaceutically salt for each breath inhaled by the human comprises at least 5 μg of treprostinil or its pharmaceutically acceptable salt.
7. The method of claim 1 , wherein the single event dose is inhaled in 3-18 breaths by the human.
8. The method of claim 6 , wherein the single event dose is inhaled in 3-18 breaths by the human.
9. The method of claim 6 , wherein the single event dose is not repeated for a period of at least 3 hours.